Navigation Links
Avitar's Notes Significance of New On-Site Oral Fluid Drug Testing Laws
Date:8/19/2007

Drug Free Workplace Programs To Become More Effective, Widespread

CANTON, Mass., Aug. 15 /PRNewswire-FirstCall/ -- Avitar, Inc. (OTC Bulletin Board: AVTI) highlights the importance of the State of Hawaii's recent updating of their workplace drug testing laws to incorporate oral fluid-based on-site technology and its associated benefits.

"The State of Hawaii's new law enabling on-site oral fluid-based drug testing dramatically improves any company's ability to promote a drug free workplace and truly manage on-the-job drug abuse," said Pete Phildius, Chairman & CEO of Avitar. "Most employers know that workplace drug abuse is as bad if not worse than ever," continued Phildius. "The convenience of on- site oral fluid testing, when compared to traditional laboratory-based urine drug testing, will play an important role in reversing this costly trend."

In response to the support of multiple trade unions and industries, Hawaii enacted a new law which went into effect July 1, 2007, allowing companies that previously used laboratory-based urinalysis to use newer on-site oral fluid- based technology.

"Drug and alcohol abuse remain a problem in Hawaii's workforce. The law will go a long way towards helping to promote a drug-free workplace. This measure provides a cost effective on-the-job alternative to lab tests that can be costly and difficult to schedule." -- Lt. Governor Aiona.

The construction industry in particular advocated the need to replace urine-based testing, noting that on-site oral fluid devices are cheaper, faster and easier to use than urinalysis. Traditional urine testing typically takes several days to obtain results, and requires applicants or employees to go to specified collections sites/clinics. On-site oral fluid technology provides initial results within 5-15 minutes at a fraction of the cost of urine lab tests. Any non-negative on-site test results can also be confirmed in a laboratory using oral fluid. Lastly, or
'/>"/>

SOURCE Avitar, Inc.

Copyright©2007 PR Newswire.

Page: 1 2

Related biology technology :

1. Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
2. Eppendorf Electroporation Application Notes Your participation is highly welcome !!!
3. General Notes on Primer Design in PCR*
4. Musicnotes reports 45 percent growth in 2006
5. Musicnotes strikes deal to distribute Sony/ATV sheet music
6. Musicnotes signs licensing deal with Christian music provider
7. Distance Education Conference Selects Sonic Foundry to Make Keynotes, Panel Presentations Available On-Demand
8. Esker Fax Engine Provides High-Performance, High-Value Fax to The Lotus Notes(R) Enterprise
9. Microfluidic analysis of multiplex PCR products for the genotyping of Helicobacter pylori
10. Maximize Viral RNA Yield from Biological Fluid
11. Genomic DNA Isolation From 1 ml of Body Fluid
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia 3